Global variations in cancer costing studies: An umbrella review.
Otuto Amarauche Chukwu, Beverley M Essue, Maansi Kashyap et al.
✦ AI-curated · Sources linked
In 30 seconds
This umbrella review analyzed 198 reviews encompassing 5784 studies on cancer costs, highlighting significant global disparities. The findings indicate that most evidence is concentrated in high-income countries, with only 2% focusing on childhood cancers. The review emphasizes the need for improved understanding of cancer affordability and financial protection, particularly in low- and middle-income countries.
Key findings
- Evidence on cancer costs is primarily from high-income countries, with low-income regions underrepresented.
- Only 2% of reviews focused on childhood cancers, while 87% concentrated on adults.
- Financial toxicity was reported in 50% of studies measuring cost burden, mainly in low- and middle-income countries.
- 79% of reviews assessed costs during the initial treatment phase, with only 8% covering the full cancer continuum.
Why it matters
Understanding the financial implications of cancer care is crucial for developing policies that ensure affordability and equity in healthcare. This review highlights the need for comprehensive data to address financial toxicity and improve patient outcomes globally.